Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 25908
IPSCIO Record ID: 227271
– the exclusive worldwide license in the Field of Use to use the Patent to manufacture and sell the Product; and,
– the right to grant sublicenses to any Patent licensed exclusively hereunder, provided that any Sublicensee agrees to be bound by the terms and conditions of this Agreement applicable to Sublicensees.
The agreement is exclusive except for the non-exclusive license granted to the U.S. government
Angiogenesis And Tumor Growth In Vivo.
2805 60/114,878 January 6, 1999 Method and Composition for Angiogenesis Inhibition
2806 60/114,877 January 6, 1999 Method and Composition for Angiogenesis Inhibition
2908 60/143,581 July 13, 1999 Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth
2909 60/143,534 July 13, 1999 'Generation And Use Of MAB XL313 To Inhibit Angiogenesis And Tumor Growth In Vivo
Anti-Angiogenesis for the Treatment of Cancer
In a process known as angiogenesis, cancer cells stimulate the formation of new blood vessels in order to bring oxygen and nutrients to rapidly-growing tumor tissue. The onset of angiogenesis is caused mainly by tumor cell production of growth factors that activate the cells that line the blood vessels. These activated cells begin to divide and lead to the remodeling of the extracellular matrix, which is a dense protein network that provides support and growth signals for blood vessels and tumors.
IPSCIO Record ID: 3661
IPSCIO Record ID: 5858
Cardio Vascu-Grow Human Fibroblast Growth Factor-1 treat patients with advanced atherosclerotic disease of their coronary arteries. This treatment, which regenerates new blood vessels in the hearts of these patients. Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low density (especially small particle) lipoproteins (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoproteins (HDL), (see apoA-1 Milano).
Issued US Patents
1. U.S. 6,268,178 entitled â€œPhage-Dependent Super-Production of Biologically Active Protein and Peptides;â€ and
2. U.S. 6,642,026 entitled â€œMethod of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.â€
3. U.S. 6,773,899 entitled â€œPhage-Dependent Super-Production of Biologically Active Protein and Peptidesâ€;
4. U.S. 6,794,162, entitled â€œPhage-Dependent Super-Production of Biologically Active Protein and Peptides;â€
Pending US Patent Applications 1.. U.S. 10/649,480 entitled â€œMethod of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis;â€ published as US Patent Application No. US 2004/0115769
IPSCIO Record ID: 227272
This agreement also contains a non-exclusive grant back from Licensee to Licensor.
Technology relates to angiogenesis, including anti-angiogenic diagnostic applications.
Angiogenesis means the growth of new blood vessels. Anti angiogenic drugs are treatments that stop tumours from growing their own blood vessels. If the drug is able to stop a cancer from growing blood vessels, it might slow the growth of the cancer or sometimes shrink it.
Licensee is engaged in research and development of biotechnology and pharmaceutical products which regulate the growth of new blood vessels.
IPSCIO Record ID: 4702
IPSCIO Record ID: 227270
– the exclusive worldwide license in the Field of Use to use the Patent to make, use and sell and to have made, have sold and sublicense the Products; and
– the right to grant sublicenses to any Patent licensed exclusively hereunder, provided that any SubLicensee agrees to be bound by the terms and conditions of this Agreement applicable to SubLicensee.
The exclusive license means exclusive except for the non-exclusive license granted to the U.S. government.
Angiogenesis, or the formation of new blood vessels, is necessary for the growth and spread of tumors. Licensee's antibodies and peptides bind to newly exposed sites on proteins, such as collagen, during the remodeling of the extracellular matrix, which occurs during angiogenesis. Objective is to establish our position as a leader in the development and marketing of specific active immunotherapy and other biological products for the treatment and control of cancer.
IPSCIO Record ID: 28258
IPSCIO Record ID: 368507
U.S. Patent 6,525,078 B1 dated February 24, 2003 entitled â€œCompound for the Treatment of Athreosclerotic-Thrombotic Pathological Conditions.
Atherosclerosis is thickening or hardening of the arteries caused by a buildup of plaque in the inner lining of an artery.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system. Blood clotting, also known as coagulation, is the body's first line of defense against bleeding.
Coronary disease (MCD) is the narrowing of the small blood vessels that branch off the coronary arteries and send oxygen-rich blood to the heart muscle. This decreases the amount of blood that goes to the heart muscle, which leads to chest pain (angina).
IPSCIO Record ID: 328338
For Other Indications for Licensed Compounds, Licensor grants a right of first refusal to obtain licenses to use Licensed Compounds for other applications or indications outside the Field.
For Rights to Related Compounds. Licensor grants the right to include within the license rights granted under the License specific Related Compounds.
The Parties are to develop and commercialize LR-3280 and certain related oligonucleotide compounds in Japan and certain other countries in Asia for the prevention or treatment of restenosis in any blood vessel following an angioplasty or similar procedure, and Licensor will supply Licensee quantities of product containing such compounds for clinical use and commercial sale.
The patents subject matter includes but is not limited to
– Method of inhibition smooth muscle cell proliferation by treating with c-myc antisense;
– Method of treating restenosis by administrating c-myr antisense;
– Method of Inhibiting collagen synthesis by treating with c-myr antisense;
– Method of treating vascular grafts to reduce stenosis by applying c-myr antisense to graft; and,
– Pharmaceutical compositions for the above methods.
Licensed Compounds means the oligonucleotide compound identified by Licensor as LR-3280, and any other phosphorothioated oligonucleotidc compounds that now or hereafter are owned or Controlled by Licensor or its Affiliates and that specifically target the mRNA transcribed from the c-myc gene, or contain four deoxyguanosine nucleotides in a row and are developed by Licensor for use in the Field.
Clinical Trial Product means a product, appropriate for use in clinical trials, containing a Licensed Compound or placebo, as applicable, in the formulation as determined by Licensee.
Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed.